Live Deal Pipeline
Deal detail
Browse Samjong KPMG's control sale, investment, and real-estate opportunities in one place.
Healthcare & BiotechPublished deal
Project Panax - Buyout
Health-supplement OEM with more than 36 years of operating history, differentiated manufacturing capabilities, and a competitive production platform
| Location | Korea |
|---|---|
| Industry | Healthcare & Biotech |
| Revenue | Contact us |
| Asking | KRW 20 billion on a 100% equity basis (negotiable) |
| Deal structure | Sale of 100% of existing shares (negotiable) |
| Financials | Five-year revenue CAGR of 25.3% and an average EBITDA margin of 13.4% over the past three years |
Investment highlights
- Positioned to benefit from increasingly sophisticated domestic demand and strong export growth in health supplements
- Able to address diverse customer requirements through a broad range of dosage forms and packaging capabilities
- High profitability and solid growth supported by a stable customer base and strong new-customer acquisition capabilities
Deal partner
Junbo Sim, Partner